Aurobindo Pharma vs Lupin: Which Stock Should You Track
- July 31, 2026
- Posted by: Ankit Jaiswal
- Category: News
Aurobindo Pharma vs Lupin: a leading Indian generics exporter with a global manufacturing footprint vs a leading Indian pharmaceutical company in respiratory and cardiovascular generics. Aurobindo …
Aurobindo Pharma vs Lupin is a comparison investors search for because the two companies represent genuinely different positions within Pharmaceuticals. This Aurobindo Pharma vs Lupin breakdown goes beyond generic labels and looks at real numbers: reach, products, the latest results each company has declared, and how each stock is positioned today. Understanding Aurobindo Pharma vs Lupin this way is more useful than a surface-level label, because it shows where each company actually stands rather than how it describes itself.
Aurobindo Pharma vs Lupin: Reach and Market Position
In the Aurobindo Pharma vs Lupin comparison, Aurobindo Pharma stands out for a Hyderabad-based drugmaker exporting to over 150 countries through 27 global manufacturing and packing facilities. This scale gives Aurobindo Pharma a distinct position within Pharmaceuticals that shapes how it competes.
Click Here – Get Free Investment Predictions
Lupin, on the other hand, is built around a Mumbai-based pharmaceutical company with a strong presence in respiratory, cardiovascular and anti-diabetic therapies across India, the US and other global markets. Comparing Aurobindo Pharma vs Lupin on reach alone shows two different growth strategies, not a single verdict.
Aurobindo Pharma vs Lupin: Key Products and Business Mix
Aurobindo Pharma’s business runs on generic drugs, active pharmaceutical ingredients, and biocatalysts through its AuroZymes division. This product mix is central to any Aurobindo Pharma vs Lupin comparison, since it explains where each company’s revenue actually comes from.
Lupin instead leans on generic and branded formulations across respiratory, cardiovascular, anti-diabetic and anti-infective therapy areas. The Aurobindo Pharma vs Lupin product comparison shows these are genuinely different businesses, not just different brand names in the same category.
Aurobindo Pharma vs Lupin: Latest Results
Looking at real numbers rather than claims, Aurobindo Pharma’s latest disclosed results show FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results have shown swings tied to US sales and destocking cycles, with profit ranging from double-digit growth to double-digit declines across recent quarters. This is the clearest evidence available for the Aurobindo Pharma vs Lupin comparison on Aurobindo Pharma’s side.
Lupin’s latest disclosed results show Positioned by the market among India’s larger generics exporters, with growth tied to US generic approvals and India branded formulation sales. Weighing Aurobindo Pharma vs Lupin on actual results, rather than headline positioning, is what separates a useful comparison from a generic one.
Compare Aurobindo Pharma and Lupin Fundamentals on the Univest Screener
Aurobindo Pharma vs Lupin: Stock and Valuation
On the market side, Aurobindo Pharma is described as: Holds USFDA, UK MHRA and other major regulatory approvals across its facility network. Lupin is described as: Tracked alongside Sun Pharma, Dr Reddy’s, Cipla and Aurobindo Pharma as one of India’s major listed pharma companies. The Aurobindo Pharma vs Lupin valuation gap often reflects how the market is pricing each company’s growth and risk profile differently.
Aurobindo Pharma vs Lupin: Quick Comparison Table
| Parameter | Aurobindo Pharma | Lupin |
|---|---|---|
| Sector | Pharmaceuticals | Pharmaceuticals |
| Market position | a leading Indian generics exporter with a global manufacturing footprint | a leading Indian pharmaceutical company in respiratory and cardiovascular generics |
| Reach | a Hyderabad-based drugmaker exporting to over 150 countries through 27 global manufacturin | a Mumbai-based pharmaceutical company with a strong presence in respiratory, cardiovascula |
| Latest results | FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results | Positioned by the market among India’s larger generics exporters, with growth tied to US generic app |
Conclusion
Aurobindo Pharma vs Lupin ultimately comes down to two companies solving similar problems in different ways. Aurobindo Pharma brings a leading Indian generics exporter with a global manufacturing footprint, while Lupin brings a leading Indian pharmaceutical company in respiratory and cardiovascular generics. Investors weighing Aurobindo Pharma vs Lupin should track both companies’ upcoming results and valuation gap rather than picking a side on reputation alone. This Aurobindo Pharma vs Lupin breakdown is a starting point, not a final verdict.
Download the Univest iOS App or Univest Android App to track Aurobindo Pharma and Lupin live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the main difference between Aurobindo Pharma and Lupin?
Ans. The main difference in the Aurobindo Pharma vs Lupin comparison lies in scale and business mix. Aurobindo Pharma is built on a leading Indian generics exporter with a global manufacturing footprint, while Lupin is positioned around a leading Indian pharmaceutical company in respiratory and cardiovascular generics.
How do Aurobindo Pharma and Lupin’s latest results compare?
Ans. Comparing Aurobindo Pharma vs Lupin on latest disclosed results: Aurobindo Pharma reported FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results have shown swings tied to US sales and , while Lupin reported Positioned by the market among India’s larger generics exporters, with growth tied to US generic approvals and India branded formulation sal.
What sector do Aurobindo Pharma and Lupin operate in?
Ans. Aurobindo Pharma operates in Pharmaceuticals and Lupin operates in Pharmaceuticals. Even where the sectors overlap, the Aurobindo Pharma vs Lupin comparison shows different product mixes and market positions.
Should I invest in Aurobindo Pharma or Lupin?
Ans. Both Aurobindo Pharma and Lupin have distinct strengths within their space. Investors comparing Aurobindo Pharma vs Lupin should review the latest quarterly results, valuation and their own risk profile, and consult a financial advisor before deciding.
What are the key products of Aurobindo Pharma?
Ans. Aurobindo Pharma’s key products and business lines include generic drugs, active pharmaceutical ingredients, and biocatalysts through its AuroZymes division.
What are the key products of Lupin?
Ans. Lupin’s key products and business lines include generic and branded formulations across respiratory, cardiovascular, anti-diabetic and anti-infective therapy areas.
How do Aurobindo Pharma and Lupin compare on market position?
Ans. On market position, Aurobindo Pharma holds a leading Indian generics exporter with a global manufacturing footprint, while Lupin holds a leading Indian pharmaceutical company in respiratory and cardiovascular generics. The Aurobindo Pharma vs Lupin comparison shows both companies lead in different ways rather than one being universally ahead.
